Which Emerging Trends Are Driving The Low-Grade Glioma Market Toward $1.84 Billion By 2029?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Is The Low-Grade Glioma Market Expected To Grow In Terms Of Size?
In recent years, the market size for low-grade glioma has exhibited robust growth. It is projected to expand from $1.39 billion in 2024, reaching $1.47 billion in 2025, exhibiting a compound annual growth rate of 5.8%. The past growth can be linked to a higher awareness of brain tumors, a surge in oncological research funding, an increase in the number of orphan drug designations, the proliferation of telemedicine, and better access to healthcare.
The market size for low-grade glioma is set to witness substantial growth in the coming years, with an estimated worth of $1.84 billion by 2029, marking a compound annual growth rate (CAGR) of 5.7%. The upswing anticipated within this forecast period can be linked to an increase in the elderly population, escalation in healthcare spending, the growing incidence of brain tumors, heightened government initiatives, and an increased occurrence and prevalence of high-grade gliomas. Key trends guiding this forecast period include improvements in imaging technologies, advancements in radiation therapies, the introduction of new chemotherapy routines, expansion in clinical trials, and the incorporation of immunotherapy.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21215&type=smp
Which Key Factors Are Fueling Growth In The Low-Grade Glioma Market?
The escalating occurrence of brain tumors is anticipated to fuel the expansion of the low-grade glioma market. Brain tumors, characterized by abnormal cell growth in the brain or nearby regions, can be either benign or malignant. The escalating occurrence is attributed to elements like heightened radiation exposure, environmental pollutants, genetic susceptibility, and aging. Low-grade glioma assists in dealing with brain tumors by leveraging sophisticated diagnostic tactics and targeted therapies such as surgery, radiation, and chemotherapy. These methods aid in slowing down tumor progression, conserving neurological functionality, and enhancing patients’ outcomes. Thus, timely detection and individualized treatment are crucial in handling other brain tumors exhibiting similar growth patterns. For example, The Central Brain Tumor Registry of the United States (CBTRUS), a not-for-profit organization based in the U.S, reported in October 2023 that in 2022, the global occurrence of primary malignant brain tumors was roughly 3.5 per 100,000. This figure was higher in wealthier nations (4.9 per 100,000) than in lower-middle (2.4 per 100,000) and low-income countries. Consequently, the surge in brain tumors’ occurrence is stimulating the growth of the low-grade glioma market.
How Is The Low-Grade Glioma Market Categorized Across Applications And Types?
The low-grade gliomamarket covered in this report is segmented –
1) By Drug Type: Trametinib; Dabrafenib; Ivosidenib; Mirdametinib
2) By Treatment: Surgery; Chemotherapy; Radiation
3) By Route Of Administration: Topical; Oral
4) By Distribution Channel: Online Pharmacies; Hospital Pharmacies; Retail Pharmacies
Which Emerging Trends Are Reshaping The Low-Grade Glioma Market Landscape?
Major players in the low-grade glioma market are emphasizing combination and targeted therapies, such as drugs that target genetic mutations, to better treat pediatric patients. These drugs are designed to interrupt specific gene-related pathways responsible for tumor growth. In May 2024, US-based Day One Biopharmaceuticals launched Tovorafenib (Ojemda), which received accelerated FDA approval. The once-weekly oral treatment targets BRAF gene alterations in children aged six months and older with unresectable or recurring low-grade glioma, offering a new option for those with limited alternatives.
Which Firms Are Making The Biggest Impact In The Low-Grade Glioma Market?
Major companies operating in the low-grade glioma market are McKesson Corporation, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Daiichi Sankyo Company Limited, Ipsen S.A., BeiGene Ltd., NovoCure Limited, Les Laboratoires Servier, Day One Biopharmaceuticals Inc., CStone Pharmaceuticals Co. Ltd., AnHeart Therapeutics Inc., Apollomics Inc., Agios Pharmaceuticals Inc., BioMed Valley Discoveries Inc., Avistone Biotechnology Co. Ltd., NextSource Biotechnology LLC, Sunesis Pharmaceuticals Inc.
Access The Complete Report Here:
https://www.thebusinessresearchcompany.com/report/low-grade-glioma-global-market-report
Which Region Holds The Greatest Opportunity For Low-Grade Glioma Market Expansion?
North America was the largest region in the low-grade glioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the low-grade glioma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=21215&type=smp
Browse Through More Reports Similar to the Global Low-Grade Glioma Market 2025, By The Business Research Company
Glioma Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/glioma-treatment-global-market-report
Adult Malignant Glioma Therapeutics Global Market Report 2025
Desmoid Tumors Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/desmoid-tumors-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
